Taiwan study tracks fingolimod safety in MS patients

NCT ID NCT04480853

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times

Summary

This study is watching for side effects in 30 adults in Taiwan who are starting fingolimod for relapsing-remitting multiple sclerosis. Participants will be followed for one year to record any safety issues like slow heart rate, eye swelling, liver problems, or low white blood cell counts. The goal is to better understand how safe this drug is in this specific population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site
RECRUITING

Taichung, 407219, Taiwan
Novartis Investigative Site
WITHDRAWN

Tainan, 704302, Taiwan
Novartis Investigative Site
RECRUITING

Taipei, 10002, Taiwan
Novartis Investigative Site
WITHDRAWN

Taipei, 11220, Taiwan
Novartis Investigative Site
WITHDRAWN

Taoyuan, 33305, Taiwan

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS